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CHAPTER 1. ABSTRACT 
Alzheimer’s disease (AD) is the most common type of dementia and is associated 
with roughly 500,000 new cases each year (2). AD is associated with the aggregation of 
two proteins in the brain, A-beta peptide (Aβ) and microtubule associated protein tau 
(MAPT). Aβ and MAPT are capable of adopting a cross-β fibrous protein structure, which 
can be reproduced and spread via nucleated polymerization and are termed amyloids. 
Despite such a broad biological impact of amyloids and prions, the mechanism of their 
initial formation in vivo remains a mystery. In this thesis, I will investigate proteins 
associated with AD, and the properties of these proteins that control their aggregation.  
Recent research has indicated that the U1 small nuclear ribonuclear protein 70 (U1-70k) 
can form detergent-insoluble aggregates in a manner specific to Alzheimer’s disease. U1-
70k is strongly correlated with Aβ and tau, both proteins known to play a highly important 
role in the Alzheimer’s disease cascade and plaque formation. It has been shown that 
misfolded forms of U1-70k can sequester natively folded U1-70k proteins and cause them 
to form insoluble aggregates, a characteristic of amyloids (8). The mechanism behind this 
conversion remains elusive, however. Our research focuses on determining which domains 
and combinations of domains of the U1-70k protein are necessary for aggregation, and we 
also examine its interactions with Aβ. Through plasmid construction, expression, and 
observation under fluorescence microscopy (FM), we demonstrate that the N(1-99) domain 
alone cannot induce aggregation, but the C(182-437) domain, combined N and M domains, 
and M(100-181) domain are capable of inducing aggregation. Further SDD-AGE and 
Western blot analyses indicate that the aggregates formed by the C(182-437) domain are 
 xi
detergent-insoluble, while those formed by the N and M domains as well as the M(100-
181) domain alone are detergent-soluble. This leads us to hypothesize that the aggregates 
formed by the M domain are reversible stress granules. Furthermore, the N and M domains 
also co-aggregate with Aβ, though the C(182-437) domain does not. We also examine tau’s 
suitability as a model in yeast for protein interactions and find that its aggregation is 
transformant-specific and cannot be cured by Hsp104, a heat shock protein found in yeast 
cells. We find that wild-type repeat domains of tau, the 244-372 amino acid region, 
aggregates are detergent-soluble.
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CHAPTER 2. BACKGROUND 
2.1 Amyloids 
A subset of diseases associated with protein misfolding, known collectively as 
amyloidosis, have become the focus of more research as advances in technology bring us 
closer to understanding the process of protein folding (9). Every protein in the body must 
be folded into its correct orientation in order to perform its designated function. An 
incorrectly folded protein cannot serve its intended purpose, and sometimes these 
misfolded proteins can take on conformations that have negative consequences for the cell. 
One category of alternative conformation for proteins is known as the amyloid form. 
Amyloids are proteins largely composed of cross-β fibril structures, and they are associated 
with over 50 human diseases, including Alzheimer’s disease (AD), Parkinson’s disease, 
and Huntington’s disease (9). These proteins aggregate in a disease-specific manner, 
becoming insoluble and preventing the body from clearing them naturally. They can block 
off sections of tissues and organs, leading to catastrophic symptoms in a variety of diseases. 
2.2 Alzheimer’s Disease (AD) 
Alzheimer’s disease (AD) is a neurodegenerative disease that worsens over time as 
protein deposits, known as plaques, continue to build in the brain. It is associated with 
aging and composes 60-80% of dementia cases. The most common symptom is memory 
loss, though over time, body functions are lost as well, ultimately leading to death. Neuron 
and synapse loss are additional symptoms of the disease, the pathology of which is marked 
by neurofibrillary tangles and senile plaques (16). The prevalence of AD is predicted to 
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quadruple by 2050 (11). The cost of caring for an AD patient in the US is $57,000 per year, 
and with demographics trending towards more elderly populations, the burden of AD will 
soon become unsustainable (15). Currently all treatments are purely symptomatic and do 
not address the underlying mechanics of the disease, largely due to a lack of understanding 
of its complex processes. Because of this gap in knowledge, the mechanisms of proteins 
involved with AD pathology have been targeted for potential AD treatments. 
2.3 Amyloid Cascade Hypothesis 
The amyloid cascade hypothesis is a theory that has dominated AD research for 
decades and is supported by significant evidence. It posits that the aggregation of the Aβ 
peptide in the brain is a vital and important step in the disease’s progression. Current 
research seems to point to this step being essential for initiating the disease, but drugs that 
have targeted Aβ production or aggregation have failed in clinical trials, leading 
researchers to question whether the whole disease process is driven by Aβ aggregation or 
whether it is simply one of the first steps in a wide-ranging and complex cascade (15). It is 
worth noting that the tau protein is also implicated as being ‘downstream’ of Aβ in the 
disease cascade, making it the focus of much AD research. Though the role of these two 
proteins in the disease cascade cannot be overstated, elevated Aβ and tau levels were found 
in 30-50% of normal, non-AD brains at death (5). This means that the aggregation of Aβ 
and tau alone cannot sufficiently explain the process of AD. Thus, other proteins and 
pathways must be examined. 
2.4 Aβ Peptide 
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The amyloid-β (Aβ) peptide has been associated with AD longer than any other 
protein. The composition and solubility of Aβ aggregates is directly linked to the degree of 
clinical dementia in AD. The larger protein from which Aβ derives, the β-amyloid 
precursor protein (APP), is associated with familial early onset AD when mutated. Aβ is 
derived from APP through sequential cleavage by secretases (16). Three types of secretases 
cleave APP. The alpha secretase’s cleavage prevents Aβ deposition, while cleavage by beta 
and gamma secretases promotes Aβ production (22). Aβ(1-40) contains 40 residues, while 
Aβ(1-42) contains 42 due to differential cleavage; Aβ(1-40) dominates amyloids, while 
both forms are found in senile plaques. It has been hypothesized that the aggregation of Aβ 
is the ‘trigger’ for the AD cascade, as discussed earlier. Aβ is also known to interact with 
a number of other proteins in the brain, including U1-70k. 
2.5 snRNP70 (U1-70k) Protein 
Recent studies have identified a new protein, U1 small nuclear ribonucleoprotein 
70kDa (U1-70k) as having potential amyloid-like properties. The U1-70k protein is known 
to be involved in the AD protein cascade, and unlike Aβ and tau, its effects have not been 
heavily studied. U1-70k is a protein component of the U1 snRNP complex in eukaryotes, 
which in turn is a component of the spliceosome. The spliceosome serves as a molecular 
machine responsible for splicing introns out of pre-mRNA that have been transcribed to 
make the final RNA message. After being processed by the spliceosome and undergoing 
other alterations, the mRNA can then be translated into protein. AD brains show 
significantly elevated levels of unspliced, non-mature RNA still containing introns (5). 
This indicates that the intron splicing process may be going unregulated due to U1-70k 
having lost its function by misfolding. That interpretation could implicate neuronal RNA 
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processing as playing a more important role in AD pathogenesis than was previously 
realized. U1-70k also appears to be disease-specific; increased U1-70k presence was 
observed only in AD brains, not in those with other neurodegenerative diseases, unlike Aβ 
and tau (5). This high specificity makes it extremely important in studying its relation to 
AD treatments. Removing the normal function of U1-70k results in increased levels of 
amyloid precursor protein, which is known to kickstart the AD disease cascade (3). This 
suggests that U1-70k may actually be upstream of Aβ. Previous studies have shown that 
U1-70k forms detergent-insoluble aggregates in AD brains, a characteristic typical of 
amyloids (8). These U1-70k aggregates appear and spread across the brain in a very similar 
pattern to the spread of tau aggregates (3). Similar aggregates seen in mild cognitive 
impairment (MCI), the early-stage precursor to symptomatic Alzheimer’s disease, suggest 
that the aggregation and amyloidogenesis of U1-70k occurs early in the disease cascade, 
making it an ideal target for preventative treatment (3). It should also be noted that another 
study has shown that in AD, U1-70k is N-terminally cleaved to a size of 40kDa. The N40K 
fragment has been shown to have toxic effects on neurons, suggesting this protein may play 
a role in neurodegeneration of AD patients (3). 
2.6 Tau Protein 
The tau protein is an important protein of interest in AD as well. This natively 
unfolded protein is normally found abundantly in the central nervous system, where it 
stabilizes microtubules (16). It is associated with disease pathologies other than AD, such 
as FTDP-17; these are collectively known as tauopathies. Due to its unfolded nature, it has 
a variety of isoforms it can take, as well as other proteins it can interact with. Normally tau 
is highly soluble, but it can aggregate when its short hydrophobic motifs form β-sheet 
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structures (16). Tau’s aggregates are toxic to the brain, and it is hypothesized that they are 
triggered by Aβ’s ‘upstream’ aggregation.  
2.7 Goals 
The main question about the role of U1-70k in AD is the same as for many other 
proteins involved in amyloid diseases: it is still unknown exactly how normal, soluble U1-
70k proteins actually become insoluble aggregates. Diner et.al. 2014 theorized that the 
process accelerates by means of aggregated U1-70k surrounding and sequestering natively 
folded U1-70k proteins, preventing them from functioning and thus forming larger 
detergent-insoluble aggregates (5). However, this still does not answer the question of how 
the aggregates appeared in the first place. The protein’s domains, which contain its 
structural information, have been suspected to play a role in its change of function. It has 
been shown that the C-terminus of U1-70k, which contains two disordered low complexity 
domains, LC1 and LC2, is necessary and sufficient for U1-70k aggregation (5). The ability 
to form aggregates was attributed to the low amino acid diversity of those LC subunits, but 
it was not explained how amino acid composition could have this effect. Additionally, 
failing to sufficiently test the other domains of the protein presents an incomplete picture 
of its properties.  
Through investigating the other domains, we can determine if they too have areas 
of low complexity and high disorder, as Diner first proposed (5). If they do not, this would 
suggest that factors other than complexity play a role in causing aggregation. Our results 
thus far show that the combined N and M domains are also capable of inducing aggregation, 
which seems to conflict with the results of Diner and Hales (14). In our experiments, we 
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will continue to use yeast as a model organism for mammalian diseases, as yeast are also 
plagued by amyloids, known as yeast prions, making them a useful tool for the study of 
human disease (10).  
It is also essential to study the interactions of U1-70k with the two most major 
proteins implicated as part of the AD cascade: Aβ and tau. By examining the relationship 
between these proteins and U1-70k, we can work towards determining the location of U1-
70k in the AD cascade. Whether it is “upstream” or “downstream” from Aβ may have 
considerable consequences for AD research.  
Previously, we had only observed aggregation in the combined NM(1-181) 
domains. We extended our investigation to other domains and combinations of domains 
within U1-70k in order to determine which are necessary for amyloid formation to occur. 
Determining which domains are responsible for aggregation will not only aid in targeting 
U1-70k for treatment, but it can aid in the understanding of what exactly causes the protein 
to aggregate, allowing for more targeted and effective treatments of AD. 
In order to study the amyloidogenic properties of U1-70k, we have cloned domains of 
the human U1-70k gene fused to the yellow-fluorescent protein (YFP) into a yeast (S. 
cerevisiae) shuttle plasmid, under an inducible copper (PCUP) promoter. We now aim to 
test the isolated N, M, and C domains to determine which domains are capable of inducing 
aggregation and, of these, which aggregates are detergent-insoluble. We also examine the 
interactions of the NM and C domains with Aβ through colocalization and assess whether 
tau in yeast can function as an accurate model for tau in other organisms, in preparation for 
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future experiments involving tau. Finally, we characterize tau’s aggregations with SDD-
AGE and SDS-PAGE.  
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CHAPTER 3. MATERIALS AND METHODS 
3.1 Yeast Media 
Yeast were grown at 30ºC. Rich yeast medium (YPD) was constructed from 2% 
peptone, 2% dextrose, and 1% yeast extract. Other media were built that lacked one or two 
amino acids, to be used as screens for plasmids with those markers. Those media were 
labeled according to the amino acid(s) they lacked; for example, -leu media was missing 
leucine. Yeast media could either be solid (with agar, on plates) or liquid (without agar, in 
flasks or bottles), depending on its intended purpose.  
3.2 Plasmid Construction 
An existing plasmid, PCUP-PHC3-YFP, (made by our collaborator Anastasia Grizel) 
was used as a backbone for all newly constructed U1-70k plasmids. The new plasmids 
were PCUP-U1-70kN(1-99)-YFP, PCUP-U1-70kM(100-181)-YFP, PCUP-U1-70kNM(1-
181)-YFP,  and PCUP-U1-70kC(181-437)-YFP. For construction, the vector plasmid PCUP-
PHC3-YFP was incubated with the restriction enzymes BamHI and Xba1 to remove PHC3, 
and to place in domains of U1-70k flanked by the same enzymes sites inserted using PCR. 
A simplified view of the plasmids is shown in Figure 1. All digests were run on an agarose 
gel to separate out the desired fragment, which was cut out of the gel and purified with a 
Monarch © DNA gel extraction kit. DNA fragments were ligated using T4 DNA ligase, 
resulting in the desired plasmid construction (U1-70k domains fused to YFP under the PCUP 
promoter).. All plasmids were verified by sequencing. For MAPT, PGPD-Tau(244-372)-
YFP was given to us by our collaborators at Saint Petersburg University, Russia.. 
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Figure 1. Diagram of plasmid construction. This example compares a newly created 
plasmid to the vector it was derived from. Each plasmid included an inducible copper 
(PCUP) promoter and a fluorescent protein (YFP). Arrows indicate recognition sites for 
restriction enzymes.  
3.3 Bacterial Transformation 
To transform plasmids into Escheria coli (E. coli) bacteria, competent cells (DH5α) 
were first thawed on ice. 5 µL of plasmid DNA were added to a microfuge tube along with 
50 µL of competent cells. The cells and DNA were mixed by flicking the tube, which was 
then placed on ice for 30 minutes. After this, the mixture was heat-shocked for 45 seconds 
at 42ºC, then placed on ice again for 2 minutes. 950 µL of fresh room temperature super 
optimal broth with catabolite repression medium (SOC medium) was added to the tube. 
SOC was prepared from super optimal broth (SOB), magnesium chloride, and glucose. The 
mixture was then incubated at 37ºC for an hour with shaking. During this time, selection 
plates of media were warmed to 37ºC. The cells were mixed by flicking and diluted if 
necessary. 50-100 µL of the cell mixture was spread onto each plate using glass beads, and 
the plates were incubated overnight at 37ºC.  
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3.4 Transformation into Yeast 
Yeast cells were transformed in accordance with the protocol described by Gietz et 
al. (13). To transform the plasmids into yeast, a pre-culture was grown in 10 mLs of YPD. 
The cells were then diluted into a 50 mL flask of fresh YPD and incubated for 2 hours. The 
culture was then transferred to a sterile Oakridge tube and centrifuged at 3,000 RPM for 
10 minutes. The supernatant was poured out, and the pellet was washed with 10 mL of 
Tris-EDTA (TE) buffer. The pellet was resuspended in 10 mLs of lithium acetate Tris-
EDTA buffer (LiAc-TE). Cells were incubated with LiAc-TE with shaking for 1 hour. 
Cells were then centrifuged and resuspended into 1mL of  LiAc-TE. For the transformation 
reaction, 100 µL of cells (per transformation) were transferred to a microfuge tube and 
incubated for 30 minutes with 10 µg of DNA (the transforming plasmid) and 20 µg of 
carrier DNA. A tube with no DNA was used as a control. After the 30 minute incubation, 
700 µL of lithium acetate polyethylene glycate Tris-EDTA buffer (LiAc-PEG-TE) was 
added to each tube , followed by a 1 hour incubation. The samples were then heat-shocked 
for 6 minutes at 42ºC, then placed at 4ºC overnight. The next day, the samples were 
centrifuged at 3000 RPM for 2 minutes. The supernatant was poured out, and the cells were 
resuspended in 250 µL of water. 250 µL of each sample were then pipetted onto plates with 
selection for the plasmid marker and allowed to grow for 3-4 days at 30ºC. 
3.5 Fluorescence Microscopy 
The yeast cultures were diluted to OD600 = 0.5. Protein expression was induced with 
4 different concentrations of copper sulfate: 0 µM, 100 µM, 200 µM, and 300 µM. The 
yeast cells were centrifuged at 3000 RPM for 10 minutes. The pellet was washed with 500 
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µL of water and transferred to a microfuge tube, where it was again centrifuged at 3000 
RPM for another 10 minutes. If necessary, the cells were diluted in another centrifuge tube 
with a 3:1 ratio of water to cells. Each mixture was then spread on a glass microscopy slide 
with a pipette tip, dried under a hood, and covered with a glass slide with 10 µL of water 
added. The slides were mounted with fast-drying nail polish. Starting from the 0 hour time 
point (0 hours after the induction), the slides were analyzed using a Olympus BX41 
microscope with an Olympus DP-71 camera from Chroma Technology Corporation. 
Photos were taken under white light and using the excitation wavelength for the yellow 
fluorescent protein. This process was completed for a total of 6 time points for each 
plasmid: 0 hours, 3 hours, 6 hours, 24 hours, 48 hours, and 72 hours. The images were 
analyzed with ImageJ, and percentage aggregation was determined by counting the number 
of cells containing aggregates as a percent of the total number of cells containing the 
plasmid.  
3.6 SDS-PAGE and Western blotting   
For SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and 
analysis with a Western blot, cells were harvested at the 6 hour time point and lysed with 
silica beads. The protein was harvested and incubated with 4x loading buffer (240 mM 
Tris-HCl pH 6.8, 8% SDS, 40% glycerol, 12% 2-mercaptoethanol and 0.002% 
bromophenol blue) at room temperature for 10 minutes. The samples were then loaded into 
a 10% SDS-polyacrylamide gel in Tris-Glycine-SDS running buffer (0.1% SDS, 192 mM 
glycine, 25 mM tris, pH 8.3) and run on the gel. After the gel was run, a PVDF membrane 
was cut to the same size as the gel, along with two pieces of Hybond-ECL nitrocellulose 
membrane. A stack was prepared, containing a sponge, filter paper, the gel, the membrane, 
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another layer of filter paper, and another sponge. The stack was placed in the Transfer-Blot 
(Bio-Rad) and covered with TAE/SDS buffer. The transference was run for 1 hour at 100 
volts. The membrane was then pre-blocked with 5% non-fat milk and probed with an 
antibody specific for YFP. The membrane was then washed, and excess reagent was 
removed. It was then wrapped in plastic wrap, put in a case to protect it from light, and 
imaged by chemiluminescence using x-ray film.  
3.7 SDD-AGE  
The SDD-AGE (semi-denaturing detergent agarose gel electrophoresis) procedure 
was carried out in much the same way as the SDS-PAGE, except that the samples were run 
in a 1.8% Tris-Acetate EDTA (TAE) agarose gel with 0.1% SDS instead of the 
polyacrylamide gel, and a Whatman membrane was used rather than the Hybond-ECL one. 
All other steps were the same. The kinetics of the proteins being run on the gel are shown 
in Figure 2. 
 
Figure 2. Kinetics of aggregate formation. A graphic displaying the differences in how 
polymers and monomers move on a SDD-AGE gel. Polymers (in this case, insoluble 
aggregates) will appear as dark, dense, slow-moving smears on a Western blot, whereas 
soluble monomers will appear as lighter, fast-moving bands.   
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3.8 Boiled Gel 
The boiled gel process was conducted in the same way as the SDS-PAGE, except 
that rather than boiling protein samples prior to loading, they were loaded without being 
boiled and run for roughly 40 min in the gel. Electrophoresis was then halted, and the wells 
were filled with fresh acrylamide to retain any aggregated protein that was still in the wells. 
After the polyacrylamide had dried, the gel was boiled in a water-tight bag for 20 minutes. 
Once it had cooled, it was returned to the electrophoresis box, and the electrophoresis 
process was continued. The Western blot was performed in the same way as described for 
SDS-PAGE. 
3.9 Yeast Mating 
The yeast pre-cultures were grown in media selective for their respective plasmid, 
along with two mating type check strains in YPD. The pre-cultures were streaked across a 
new YPD plate in two lines. Cells from the mating type check strains were then streaked 
perpendicular to the first line, then the plates were incubated overnight. The following day, 
the plates were velveteened to drop-out media selective for the markers of both plasmids 
to screen for the diploids. The drop-out media plates selective for diploids were then 
incubated for 2 days to allow colonies to grow. An overview of how this procedure was 
performed for the mating of U1-70k and Aβ is shown in Figure 3. 
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Figure 3. Yeast mating experimental design. This figure shows how the diploid 
strains containing Aβ(1-42) and U1-70kNM(1-181) or U1-70kC(182-437) were created 
through yeast mating.  The plasmids containing U1-70k have a LEU2 marker, and the Aβ 
plasmid has a URA3 marker, allowing them to be screened with -URA-Leu plates to select 
for diploids. 
3.10 Colocalization 
For colocalization studies, plasmids were constructed according to the procedure 
described in 2.2.1 with differing genes for fluorescent proteins. In this case, cyan 
fluorescent protein (CFP) and yellow fluorescent protein (YFP) were to distinguish 
between the two proteins of interest. The plasmids were then transformed into yeast 
according to the procedure in 2.4, mated as described in 2.8, and imaged as described in 
2.5. One image was taken using the filter with the emission wavelength for CFP and one 
with the filter with the emission wavelength for YFP filter, as well as one brightfield image. 
The CFP and YFP images were merged into one using software provided by Olympus, and 
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the resulting image was analyzed with ImageJ to determine what percentage of cells 

















CHAPTER 4. CHARACTERIZING THE DOMAINS OF U1-70K 
4.1 Introduction 
The U1 small nuclear ribonucleoprotein-70k (U1-70k) is a spliceosome component 
of the U1 snRNP. It has 3 domains: the N-terminus, the M domain containing the RNA 
recognition motif (RRM), and the C domain. The C domain is known to contain 2 regions 
of low amino acid complexity (5) thought to be essential to its aggregation. One of those 
low-complexity regions has been shown to interact with tau from AD brains but not from 
other tauopathies, indicating that it may be disease-specific (14). We hypothesize that the 
C domain controls the aggregation of U1-70k and that its aggregates are detergent-
insoluble, like those found in AD brains. 
4.2 Results 
Our results indicate that the U1-70kN(1-99) domain does not form aggregates at any 
time point or concentration of copper sulfate, as seen in Table 1.  
Table 1. Percent aggregation of Cup-U170kN-YFP over time. The N domain 
shows only diffuse fluorescence under FM and does not form aggregates at any time 
point or concentration of CuSO4. 
                          








We also found that the U1-70kNM(1-181) domain is able to form fluorescent foci 
without the presence of the C domain, as seen in Figure 4. Two SDD-AGE analyses were 
performed on separate samples of U1-70kNM(1-181) proteins, with conflicting results, as 
can be seen in Figure 5. The first seemed to indicate that the NM domains could form 
detergent-insoluble aggregates, while the second showed that these aggregates were in fact 
detergent-soluble. Another cleaner SDD-AGE will be performed to clear up any confusion 
surrounding the nature of these aggregates. 
 
Figure 4. Percent aggregation of Cup-U170kNM(1-181)-YFP over time. Cup-
U170kNM(1-181)-YFP forms fluorescent foci over time, peaking at 6 hours post-induction 
with CuSO4 and decreasing to nearly 0% aggregation by 72 hours. All error bars, unless 
otherwise indicated, represent standard deviation. 
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Figure 5. SDD-AGE results for U1-70kNM. The first SDD-AGE (left) seems to 
indicate that U1-70kNM(1-181) aggregates are detergent-insoluble, but the second one 
(right), which includes protein samples from 4 different time points, shows them moving 
as soluble monomers. These experiments were conducted using two different 
transformants. 
Our results indicate that the U1-70kC(182-437) domain is able to form fibril-like 
aggregates in a [psi-][pin-] strain when over-expressed, as seen in Figure 6. The aggregates 
formed by this domain are detergent-insoluble, as shown by the SDD-AGE in Figure 7. 
They travel as a polymer rather than a monomer, forming a slowly migrating blur on the 
membrane, as displayed in Figure 2. 
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Figure 6. Percent aggregation of PCUP-U170kC(182-437)-YFP over time. PCUP-
U170kC(182-437)-YFP forms fluorescent foci over time. Aggregation remains relatively 
constant after 6 hours apart from a slight dip at 48 hours. The aggregates are still 
significantly present at 72 hours post-induction. 
 
Figure 7. SDD-AGE results for PCUP-U170kC(182-437)-YFP.  PCUP-U170kC-YFP 
forms detergent-insoluble aggregates, as can be seen in the 6, 24, and 72 hour lanes. No 
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protein is present in the 0 hour lane as induction had just begun at that point. Slow-
moving polymers are present in all other lanes. 
As can be seen in Figure 8, results for the M domain alone indicate that it too can 
cause the appearance of fluorescent foci, as we had predicted, indicating the the 
aggregation of the NM(1-181) fragment may be controlled by the M domain. The Western 
blot in Figure 9 shows that these types of aggregates formed by the M domain are in fact 
detergent-soluble, like those formed by the N and M domains together. The control 
plasmids containing just PCUP-YFP did not aggregate in any experiment, displaying the 
necessity of U1-70k domains in aggregation. It is also worth noting that for the NM and M 
domains, the percentage of cells displaying aggregates peaked at the 6 hour mark and 
gradually fell off to a consistent 0% at the 72 hour mark. This pattern was not consistent 
for the C domain, which kept up a relatively stable percentage aggregation over time. 
 
Figure 8. Percent aggregation of PCUP-U170kM(100-181)-YFP over time. PCUP-
U170kM-YFP forms fluorescent foci over time, peaking at 6 hours post-induction with 
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copper sulfate and decreasing to nearly 0% aggregation by 72 hours, just as was seen in 
PCUP-U170kNM(1-181)-YFP. 
 
Figure 9. SDD-AGE results for PCUP-U170kM-YFP. The proteins only run as 
monomers. The 0 hour lane shows no protein presence due to induction having just 
begun. The 24 hour lane seems to be blank, but this may be due to the amount of protein 
loaded. The strongest protein presence is at the 6 hour time point, in accordance with the 
FM results. 
We also performed colocalization studies between aggregating domains of U1-70k 
and Aβ in order to determine if the proteins are interacting. Colocalization of the aggregates 
would imply a relationship between the proteins; namely, that the aggregation of Aβ would 
be causing the aggregation of U1-70k. It was found that PCUP-U1-70kNM(1-181)-YFP was 
able to colocalize with PCUP-Aβ(1-42)-CFP at the tested 6 and 24 hour time points, as can 
be seen in Figure 10. The aggregates themselves can be seen in Figure 11. However, PCUP-
U1-70kC(182-437)-YFP did not colocalize with PCUP-Aβ(1-42)-CFP, as shown in Figure 
12. The aggregates remained separate and were not overlaid, as shown in Figure 13. 
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Figure 10. Colocalization of PCUP-U1-70kNM(1-181)-YFP and Cup-Aβ(1-42)-CFP 
over time. The NM domain of U1-70k colocalizes clearly with Aβ(1-42). By 24 hours, 
nearly all of the cells expressing both CFP and YFP-tagged aggregates (Aβ(1-42) and U1-
70kNM(1-181) respectively, can be seen as colocalized. 
 
Figure 11. Fluorescence microscopy results of PCUP-U1-70kNM(1-181)-YFP and 
PCUP-Aβ(1-42)-CFP colocalization at 6 hours. Pictures were taken under cyan light 
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(CFP), yellow light (YFP), and white light (brightfield). The CFP and YFP images were 
overlaid to create the “merged” image, allowing us to determine whether the aggregates 
were colocalized. Nearly all cells expressing both types of aggregates displayed 
colocalization. 
 
Figure 12. Colocalization of Cup-U1-70kC-YFP and Cup-Aβ-CFP over time. The C 
domain of U1-70k does not colocalize with Aβ(1-42) at any time point. Even samples with 




Figure 13. Fluorescence microscopy results of PCUP-U1-70kC(182-437)-YFP and 
Cup-Aβ(1-42)-CFP colocalization at 6 hours. The aggregates of each type did not 
colocalize, usually manifesting in separate cells or, when they did occur in the same cell, 
segregating to opposite ends of the cells. 
4.3 Discussion 
The over-expression of U1-70kN(1-99) results in diffuse fluorescence. This alters 
our initial hypothesis that the N-domain (an unstructured domain) was causing the 
aggregation of the U1-70kNM domain. These results match findings by Diner et al. 
suggesting that the N domain cannot aggregate on its own, despite containing an 
unstructured domain. The results of the C domain support existing findings indicating the 
aggregation-inducing abilities of that domain. The fact that the N and M domains combined 
can cause aggregation of some sort would indicate that the C domain is not actually 
necessary to cause aggregation. Because the NM domains aggregated together, but the N 
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domain did not aggregate by itself, we hypothesize that the M(1-181) domain is responsible 
for aggregation of the NM(1-181) domain.  
The results of the SDD-AGE analyses indicate that only the C(182-437) domain is 
capable of forming detergent-insoluble aggregates. This is in agreement with previously 
published data by Diner et al. This is in assumption that the second SDD-AGE for the 
NM(1-181) domains is correct, which suggests that the aggregates formed by the M(100-
181) domain may be of a different type than those formed by the C domain. For now, our 
results seem to support the second SDD-AGE, as the aggregates formed by the M(100-
181) domain alone were soluble and the N(1-99) domain cannot form aggregates. It follows 
to conclude that, until we can perform another SDD-AGE, the aggregates formed by the 
NM(1-181) domains together are likely soluble. Our evidence as of now seems to point to 
the aggregations of the M(100-181) domain actually being stress granules. Stress granules 
are aggregations of proteins and RNA that can occur when the cell is under stress. Unlike 
amyloids, they are reversible and can dissociate over time. They can be caused by a number 
of factors, including heat, cold, and overexpression of proteins (18). It should be noted that 
percentage aggregation of the C(182-437) domain remains relatively constant over time 
and is still very much present at 72 hours, while for the NM(1-181) and M(100-181) 
domains, aggregation peaks at 6 hours and decreases after that to almost 0% by 72 hours. 
If these aggregations were stress granules, it would explain their disappearance over time, 
as stress granules can dissociate naturally. It would also account for their detergent-
solubility, as opposed to the aggregations formed by the C domain. U1-70kNM’s 
colocalization with Aβ could be due to Aβ’s aggregation triggering the formation of stress 
granules in the same location as Aβ. It is also important to recall that the M domain of U1-
 26
70k is the RNA-binding domain, which could be related to the formation of these RNA-
based stress granules.  
4.4 Conclusions 
 Of the domains of U1-70k, 2 out of 3 are capable of inducing aggregation on their 
own: the M(100-181) and C(182-437) domains. Only the N(1-99)-terminus domain 
is incapable of inducing aggregation.  
 The aggregates formed by the M(100-181) and C(182-437) domains are likely 
different types of aggregates, with the M(100-181) domain potentially forming 
stress granules and the C(181-437) domain forming fibril-like detergent-insoluble 
aggregates similar to the ones found in AD. This would correlate with the findings 
of Diner et al. who state that the C domain alone is necessary and sufficient for 
detergent-insoluble aggregation.  
 The aggregates formed by the NM(1-181) domains of U1-70k can colocalize with 
those formed by Aβ, while the aggregates formed by the C domain cannot.  
4.5 Future Directions 
The next step in the investigation of U1-70k will be to construct a plasmid containing 
all 3 domains of U1-70k (i.e. its full length) and test it as we have tested the previous 
domains for aggregation and detergent-insolubility. To answer the question about the 
nature of the M domain’s aggregates, we intend to run colocalization tests of Cup-U1-
70kM-YFP and Pub1, a marker for stress granules. Colocalization tests will also be run 
between Cup-U1-70kM-YFP and Cup-Aβ(1-42)-CFP to determine if colocalization 
still occurs without the N domain.  
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CHAPTER 5. ANALYZING TAU’S AGGREGATIONS 
5.1 Introduction 
Microtubule-associated protein tau (MAPT, or tau) is a natively unfolded protein 
usually found in one of 6 isoforms formed by alternative splicing. It is located in the central 
nervous system, where it stabilizes microtubules in the brain. Under normal conditions it 
is soluble, but in certain cases it can become insoluble and form β-sheet structures as it 
aggregates. Tau became associated with AD after it was discovered that the accumulation 
of amyloidogenic tau in the human brain correlates with the cognitive decline seen in AD 
and other tauopathies (19). When tau begins to nucleate, it loses its native function, and the 
microtubules it had previously stabilized become disorganized, forming neurofibrillary 
tangles (NFTs) (20). Because tau has proved to be dangerous in humans, we wish to 
determine if tau can be used in yeast as an accurate model for protein interactions and 
determine if its aggregates are detergent-insoluble. Yeast have proven to be an invaluable 
tool in the study of protein aggregation, with a lot of our understanding coming from in 
vitro and microcellular models. We hypothesize that tau will behave similarly in yeast as 
it does in humans. We also hypothesize that the Hsp104 protein will be able to cure the 
aggregates formed by tau. Hsp104 is a heat shock protein that appears to be able to cure 
some tau aggregations in certain strains of yeast. 
5.2 Results 
We first assessed the validity of the tau model in yeast and found that the repeat 
domain of tau, the 244-372 amino acid domain, could aggregate in any of the prion-free, 
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prion-containing, or diploid strains that we tested it in. However, we found that the repeat 
domain of tau’s aggregation was transformant-specific, as can be seen in Figure 14. Since 
the aggregation properties of the repeat domain of tau are transformant specific, a 
representative transformant that did not aggregate was used for subsequent experiments 
and will be referred to as the non-aggregation strain. Two representative transformants 
were selected that did aggregate and were used in experiments and will be referred to as 
the aggregation strains #1 and #2.  
 
Figure 14. Tau aggregation is transformant specific in various yeast strains. The repeat 
domain of tau can aggregate in a prion-free strain ([psi-][pin-]), in a strain with the prion 
caused by the Rnq1 protein ([psi-][PIN+]), in a strain with the Sup35 prion ([PSI+]), and in 
a diploid strain. It was essential to prove that tau can aggregate in a diploid strain, as it we 
would look for aggregation of tau in conjunction with Hsp104, which would be done via 
mating. 
We then tested three strains of tau- two aggregating strains and one non-aggregating 
strain, as well as a Cup-YFP control- to determine if their aggregates were detergent-
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insoluble. SDS-PAGE results with a GFP antibody showed that all the strains and the 
control were being expressed, while the loading control with a RPL3 antibody showed that 
the gel lanes were evenly loaded with the samples. Figure 15 shows the results of the SDD-
AGE. It was observed that all the proteins in both the aggregating and non-aggregating 
strains traveled as monomers.  
 
Figure 15. SDD-AGE results for PGPD-Tau(244-372)-YFP. The SDD-AGE shows 
that all proteins traveled as monomers, leaving no smears indicating high molecular weight 
aggregates. The results of the aggregating strains match those of the non-aggregating 
strains, indicating that the aggregates are not detergent-insoluble. 
 The results of the boiled gel match the results of the SDD-AGE; as seen in Figure 
16, the unboiled samples match the boiled samples in molecular weight. There are no high 
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molecular weight aggregates that would indicate detergent insolubility. Therefore, all these 
aggregates must be composed of soluble monomers. 
 
 Figure 16. Boiled gel results for PGPD-Tau(244-372)-YFP. Apart from an unclear 
smear in the last lane, there appear to be no differences between the boiled and unboiled 
samples, suggesting that no high molecular weight aggregates are present.   
Figure 17 shows the results of the SDS-PAGE conducted on the aggregating and 
non-aggregating tau samples. All the proteins are being expressed, but the same plasmid 
seems to be expressed differently in its aggregating and non-aggregating forms. This leads 
us to hypothesized, based off the results below, that the aggregating form has been 
phosphorylated, leading to the difference in molecular weight. Figure 18 displays the 
differences between aggregating and non-aggregating tau strains under FM. 
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Figure 17. SDS-PAGE results for PGPD-Tau(244-372)-YFP. The same plasmid is 
expressed differently between the aggregating and non-aggregating strain. The 
aggregating strains appear to have a higher molecular weight than the non-aggregating 
strains, possibly indicating that phosphorylation is occurring in the aggregating strains. 
 
Figure 18. Fluorescence microscopy images of tau samples. Non-aggregating 
strains display no tau aggregates, whereas aggregating strains often display multiple 
aggregates per cell. 
Through yeast mating, we created diploid strains containing either the non-
aggregation strain on aggregation strain of tau along with the plasmid PGPD-Hsp104. We 
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found aggregates only in the aggregating strains, as expected, and we found that Hsp104 
does not significantly cure tau aggregations. Aggregating strains with Hsp104 experienced 
a slight decrease, however not statistically significant, in both percent aggregation and 
number of aggregates per cell, as shown in Figure 19.  
 
Figure 19. Effects of Hsp104 on tau aggregation. (A) Percent aggregation of tau in 




significantly decrease the percent of cells showing aggregation in either of the aggregating 
strains. (B) Average number of tau aggregates per yeast cell. Hsp104 does not significantly 
decrease the average number of tau aggregates per cell. 
 
Figure 20. Aggregates of tau in various yeast strains. Tau aggregation is transformant-
specific and occurs consistently in the same strains. No aggregates were seen in the 
designated non-aggregating strain or the empty control plasmid. Hsp104 did not 
significantly cure tau aggregates. 
5.3  Discussion 
Our results confirm that tau in yeast is an accurate model for various tauopathies. It 
behaves similarly in yeast as it does in humans, implying that its properties are inherent to 
the protein itself and not its cellular environment. The fact that it still aggregates in diploid 
strains may be important in further colocalization experiments or any tests involving yeast 
mating. Despite our expectations, Hsp104, a known yeast disaggregase, did not 
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significantly cure tau aggregates. On average, a slight dip in percentage aggregation was 
observed, but it was not significant enough to qualify as curing the tau aggregates. There 
are several potential explanations for this. Firstly, tau is not a native yeast protein, so it is 
possible that Hsp104, a yeast disaggregase, would not be able to cure a non-yeast protein. 
Alternatively, tau may form aggregates that are not sensitive to Hsp104; the usual targets 
of Hsp104 are rich in glutamine and asparagine, while tau is not. We also found that, 
despite the focus on insoluble aggregates of proteins involved in AD, even the aggregating 
strains of tau did not form detergent-insoluble aggregates, forming soluble monomers 
instead. This is interesting, as it would seem to corroborate the claims of Fox et al. that 
soluble species of tau, not neurofibrillary tangles, are the toxic species observed in AD that 
are responsible for the disruption of hippocampal function (21). 
5.4 Conclusions 
 MAPT repeat domain 244-372 can form fluorescent foci in yeast strains in the 
presence and absence of pre-existing prions; however, its aggregation is 
transformant-specific.  
 Our data indicates that the wild-type repeat domain aggregates are not not 
detergent-insoluble.  
 Over-expression of Hsp104 does not cure the strains containing tau aggregates.  
5.5 Future Work 
We have preliminary data to suggest that the aggregation of a pro-aggregation mutant of 
the repeat domain is capable of forming aggregates; however, this is not transformant 
specific. We will be testing the pro-aggregation strain of tau, as well as the full-length tau, 
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with SDD-AGE to determine if their aggregates are also detergent-insoluble. To determine 
if the aggregating strains of tau are in fact phosphorylated, we plan to run a Phos-tag gel 
on the aggregating and non-aggregating strains. Finally, we plan to test for colocalization 

















APPENDIX A. TABLES OF STRAINS, PRIMERS, PLASMIDS, AND 
DATA  
Table A1: Strains used in this work 








a  ade1-14  his3-Δ200 or 11,15  leu2-3,112  lys2  trp1-Δ  ura3-52  Ψ- 














Table A2: Plasmids used in this work 
Plasmid name Yeast marker Collection 
number 
Source 
pCUP1-YFP Leu2 1585 Chernoff Russian 
Lab 




URA3 1592 Chernoff Russian 
Lab 
pCup1-U1-70kNM-YFP  Leu2 1600 Chernoff Lab 
pCup1-Abeta(1-42)-CFP URA3 1607 Chernoff Lab 












Table A3: Primers used in this work 





1263 Forward primer for amplifying the N-terminal region of 
U1-70k, plus adding a BamHI restriction site 
U1-70kN 
XbaI Rev 
1264 Reverse primer for amplifying the N-terminal region of U1-
70k, plus adding a XbaI restriction site 
U1-70k RRM 
XbaI Reverse 
1265 Reverse primer for amplifying the RRM region of U1-70k, 
plus adding a XbaI restriction site 
U1-70kC 
BamHI For 
1266 Forward primer for amplifying the C-terminal region of 
U1-70k, plus adding a BamHI restriction site 
U1-70k Full 
Rev 
1267 Reverse primer for amplifying the Full region of U1-70k, 
plus adding a XbaI restriction site 
U1-70kM 
BamHI F 
1308 Forward primer for amplifying U1-70KM  (100-181) with 
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